Skip Navigation



Annals of Oncology Advance Access published online on June 2, 2009
Annals of Oncology, doi:10.1093/annonc/mdp032
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/9/1596    most recent
mdp032v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Neyns, B.
Right arrow Articles by De Greve, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neyns, B.
Right arrow Articles by De Greve, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma

B. Neyns1,*, J. Sadones1, E. Joosens2, F. Bouttens3, L. Verbeke4, J.-F. Baurain5, L. D'Hondt6, T. Strauven7, C. Chaskis8, P. In't Veld9, A. Michotte10,11 and J. De Greve1

1 Department of Medical Oncology, UZ Brussel, Brussels
2 Department of Medical Oncology, ZNA Middelheim, Antwerp
3 Department of Radiation therapy, AZ St Lucas, Ghent
4 Department of Radiation therapy, OLV Aalst, Aalst
5 Department of Medical Oncology, Cliniques Universitaires St Luc, Brussels
6 Department of Medical Oncology, Centre Hospitalier Notre-Dame et Reine Fabiola, Charleroi
7 Department of Neurology, Sint-Augustinus, Antwerp
8 Department of Neurosurgery
9 Department of Experimental pathology
10 Department of Neurology
11 Department of Neuropathology, UZ Brussel, Brussels, Belgium

* Correspondence to: Prof. B. Neyns, Department of Medical Oncology, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium. Tel: +3224776415; Fax: +3224776012 E-mail: bart.neyns{at}uzbrussel.be

Background: To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with recurrent high-grade glioma (HGG) after failure of surgery, radiation therapy, and chemotherapy.

Patients and methods: In this two-arm, open-label, phase II study patients were stratified according to their epidermal growth factor receptor (EGFR) gene amplification status. Cetuximab was administered intravenously at a dose of 400 mg/m2 on week 1 followed by weekly dose of 250 mg/m2. The primary end point for this study was the response rate in both study arms separately.

Results: Fifty-five eligible patients (28 with and 27 without EGFR amplification) tolerated cetuximab well. Three patients (5.5%) had a partial response and 16 patients (29.6%) had stable disease. The median time to progression was 1.9 months [95% confidence interval (CI) 1.6–2.2 months]. Whereas the progression-free survival (PFS) was <6 months in the majority (n = 50/55) of patients, five patients (9.2%) had a PFS on cetuximab of >9 months. Median overall survival was 5.0 months (95% CI 4.2–5.9 months). No significant correlation was found between response, survival and EGFR amplification.

Conclusions: Cetuximab was well tolerated but had limited activity in this patient population with progressive HGG. A minority of patients may derive a more durable benefit but were not prospectively identified by EGFR gene copy number.

cetuximab, EGFR, glioblastoma

Received for publication November 11, 2008. Revision received January 25, 2009. Accepted for publication January 26, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.